英国正版365
Promote a healthier life
for humankind through
advancements in science
Science-based
Benefit the patients with
high-quality medication as
we determined to innovate
Innovation-driven
Build a leading global
biopharmaceutical group
to serve more
Going Global
Fulfill social responsibilities
through accountable actions
Embrace Social
Responsibilities
Explore who we are
About us
Innovation is the core of our development strategy
Partnering
We are actively looking for synergistic partnerships
Walk into Hengrui
Est.
1970
New Molecular Entity drugs marketed in China
27
Other innovative drugs marketed in China
6
SH 600276
HK 1276
Est.
1970
Marketed Innovative Products in China
8
Partnered Innovative Product Launched
1
SH 600276
HK 1276
Pipeline
Our innovative pipeline covers the most of major therapeutic areas and continues to grow
Pipeline
Our innovative pipeline covers the most of major therapeutic areas and continues to grow
Investor
Enhance communication between our company and investors
Media
Hengrui Pharma Reports 2026 Interim Results as Innovation and Globalization Continue to Drive Business Momentum
Media
HbA1c Reduction of Up to 2.78%: Hengrui Pharma Reports Positive Topline Data from Phase 3 Trial in China of GLP-1/GIP Dual Receptor Agonist Ribupatide Injection in Adults with Type 2 Diabetes Inadequately Controlled with Oral Antidiabetic Treatment
Media
HbA1c Reduction of Up to 2.67%: Hengrui Pharma Reports Positive Topline Data from Phase 3 Trial in China of GLP-1/GIP Dual Receptor Agonist Ribupatide Injection in Treatment-Naïve T2DM Patients
